[Immunotherapy: a new alternative treatment for head and neck squamous cell carcinoma].
In the past decades, prognosis of head and neck squamous cell carcinoma (HNSCC) has not improved even though treatment has made substantial progress. Since the description of immune response against some cancers, antitumoral immunotherapy has been studied to be used as adjunctive treatment in various cancer types. This article review contributions made in the field of immunotherapy on HNSCC in the past few years. It appears that this approach may play an important role in the treatment of head and neck squamous cell carcinoma. Among various TAAs, cancer testis antigens family may be promising candidates for specific immune therapy in HNSCC. Ongoing studies will confirm whether expression CTAs generate an immune response in clinical vaccine trials.
Bron
Luc
L
Service d'ORL et de chirurgie cervicofaciale, CHUV, Lausanne, Suisse. luc.bron@chuv.ch
Romero
Pedro
P
D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000628:therapy*; D006258:Head and Neck Neoplasms / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy / Q000379:methods; D019139:Tumor Escape
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines